Brainstorm Cell Therapeutics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Jacob A Frenkel, a Director of Brainstorm Cell Therapeutics Inc., received 100,000 shares of common stock on July 24, 2026.
OQB
Peter Joe Pitts, Executive Chairman and a Director of Brainstorm Cell Therapeutics Inc., received 900,000 shares of common stock on July 24, 2026.
OQB
BrainStorm Cell Therapeutics CEO Chaim Lebovits was granted 1.8 million restricted stock units, with half vesting immediately.
OQB
EVP & Chief Business Officer Uri Yablonka received an award of 150,000 restricted stock units from BrainStorm Cell Therapeutics.
OQB
Interim CFO Alla Patlis received an award of 100,000 restricted stock units from BrainStorm Cell Therapeutics.
OQB
BrainStorm Cell Therapeutics director Jacob A. Frenkel was granted 200,000 restricted stock units as part of the company's 2014 Global Share Option Plan.
OQB
BrainStorm Cell Therapeutics director Irit Arbel was granted 120,000 restricted stock units as part of the company's 2014 Global Share Option Plan.
OQB
Director Menghisteab Bairu was granted 150,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).
OQB
Director Anthony J. Polverino was granted 150,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).
OQB
Director Hartoun Hartounian was granted 225,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).
OQB
Director Stacy Lindborg was granted 150,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).
OQB
Director Nir Naor was granted 180,000 stock options in BrainStorm Cell Therapeutics Inc. as part of the company's incentive plan.
OQB
Director Ibrahim B. Dagher was granted 225,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).
OQB
Ibrahim B. Dagher, Chief Medical Officer of Brainstorm Cell Therapeutics, acquired 50,000 shares of restricted stock on January 1, 2025, under the company's 2014 Global Share Option Plan.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, was granted 120,000 shares of restricted stock on January 1, 2025, according to a Form 4 filing.
OQB
Director Jacob A. Frenkel acquired 40,000 shares of Brainstorm Cell Therapeutics through restricted stock units, vesting in two tranches.
OQB
Director Anthony J. Polverino acquired 24,000 shares of Brainstorm Cell Therapeutics through a restricted stock unit award.
OQB
Uri Yablonka, EVP & Chief Business Officer of Brainstorm Cell Therapeutics, received stock awards and restricted stock units on January 1, 2025.
OQB
Alla Patlis, Interim CFO & Controller of Brainstorm Cell Therapeutics, reports acquiring 40,000 shares of restricted stock on January 1, 2025, under the company's 2014 Global Share Option Plan.
OQB
Director Naor Nir reports acquisition and disposal of Brainstorm Cell Therapeutics stock, including restricted stock units and adjustments for a reverse stock split.
OQB
Director Stacy Lindborg reports acquiring 20,000 shares of Brainstorm Cell Therapeutics through restricted stock units.
OQB
Hartoun Hartounian, EVP and COO of Brainstorm Cell Therapeutics, received 50,000 shares of restricted stock on January 1, 2025, following a 1-for-15 reverse stock split.
OQB
A Brainstorm Cell Therapeutics director, Menghisteab Bairu, acquired 24,000 restricted stock units on January 1, 2025.
OQB
Director Irit Arbel reports acquisition of Brainstorm Cell Therapeutics common stock and adjustments due to a reverse stock split.
OQB
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired additional shares of the company's common stock through multiple transactions.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous Form 4 to correct a transaction code related to a purchase of common stock.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, amends a previous SEC Form 4 filing to correct transaction codes related to common stock purchases.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous Form 4 to correct transaction codes related to common stock purchases.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous Form 4 to correct an administrative error regarding the transaction code for a common stock purchase.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous SEC Form 4 to correct a transaction code related to a purchase of common stock.